These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 152171)

  • 21. Capsular polysaccharides of Cryptococcus neoformans.
    Bhattacharjee AK; Bennett JE; Glaudemans CP
    Rev Infect Dis; 1984; 6(5):619-24. PubMed ID: 6209768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Detection of anti-Cryptococcus neoformans antibodies in 3 groups of human sera].
    Martínez Machín G; Alvarez Bernal LP; Fernández Andreu C; Llop Hernández A
    Rev Cubana Med Trop; 1992; 44(2):141-4. PubMed ID: 9768206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cryptococcus neoformans infection can elicit protective antibodies in mice.
    Mukherjee J; Scharff MD; Casadevall A
    Can J Microbiol; 1994 Oct; 40(10):888-92. PubMed ID: 8000967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan.
    Maitta RW; Datta K; Pirofski LA
    Vaccine; 2004 Sep; 22(29-30):4062-8. PubMed ID: 15364457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A.
    Cherniak R; Reiss E; Slodki ME; Plattner RD; Blumer SO
    Mol Immunol; 1980 Aug; 17(8):1025-32. PubMed ID: 6777664
    [No Abstract]   [Full Text] [Related]  

  • 26. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals.
    Deshaw M; Pirofski LA
    Clin Exp Immunol; 1995 Mar; 99(3):425-32. PubMed ID: 7882565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-glucuronoxylomannan IgG1 specific antibodies production in Cryptococcus neoformans resistant mice.
    Parra C; González JM; Castañeda E; Fiorentino S
    Biomedica; 2005 Mar; 25(1):110-9. PubMed ID: 15962907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of serological and chemical characteristics of capsular polysaccharides of Cryptococcus neoformans var. neoformans serotype A and Cryptococcus albidus var. albidus.
    Ikeda R; Matsuyama H; Nishikawa A; Shinoda T; Fukazawa Y
    Microbiol Immunol; 1991; 35(2):125-38. PubMed ID: 1886490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune response to Cryptococcus neoformans soluble polysaccharide. I. Serological assay for antigen and antibody.
    Kozel TR; Cazin J
    Infect Immun; 1972 Jan; 5(1):35-41. PubMed ID: 4570986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Production of specific antibody to Cryptococcus neoformans by hybridomas in vitro.
    Hall NK; Blackstock R
    Sabouraudia; 1981 Jun; 19(2):157-60. PubMed ID: 7020113
    [No Abstract]   [Full Text] [Related]  

  • 31. Elucidating the immunological function of the Cryptococcus neoformans capsule.
    Vecchiarelli A; Pericolini E; Gabrielli E; Kenno S; Perito S; Cenci E; Monari C
    Future Microbiol; 2013 Sep; 8(9):1107-16. PubMed ID: 24020739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody efficacy in murine pulmonary Cryptococcus neoformans infection: a role for nitric oxide.
    Rivera J; Mukherjee J; Weiss LM; Casadevall A
    J Immunol; 2002 Apr; 168(7):3419-27. PubMed ID: 11907100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Detection of capsular polysaccharide antigen of Cryptococcus neoformans in patients with AIDS and neurocryptococcosis in São Paulo, Brazil].
    Calvo B; Fischman O; Castelo Filho A; Reis Filho J; Del Bianco R; Barbosa RM; Zaror L
    Rev Inst Med Trop Sao Paulo; 1991; 33(6):485-90. PubMed ID: 1844979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unexpected diversity in the fine specificity of monoclonal antibodies that use the same V region gene to glucuronoxylomannan of Cryptococcus neoformans.
    McFadden DC; Casadevall A
    J Immunol; 2004 Mar; 172(6):3670-7. PubMed ID: 15004170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Capsular reactions of Cryptococcus neoformans with polyspecific and oligospecific polyclonal anticapsular antibodies.
    MacGill TC; MacGill RS; Kozel TR
    Infect Immun; 2001 Feb; 69(2):1189-91. PubMed ID: 11160020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cryptococcus neoformans induces macrophage inflammatory protein 1alpha (MIP-1alpha) and MIP-1beta in human microglia: role of specific antibody and soluble capsular polysaccharide.
    Goldman D; Song X; Kitai R; Casadevall A; Zhao ML; Lee SC
    Infect Immun; 2001 Mar; 69(3):1808-15. PubMed ID: 11179358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans polysaccharide that elicit protective and nonprotective antibodies.
    Nakouzi A; Valadon P; Nosanchuk J; Green N; Casadevall A
    Infect Immun; 2001 May; 69(5):3398-409. PubMed ID: 11292763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A critical review of the role of precipitins in hypersensitivity pneumonitis.
    Burrell R; Rylander R
    Eur J Respir Dis; 1981 Oct; 62(5):332-43. PubMed ID: 7047184
    [No Abstract]   [Full Text] [Related]  

  • 39. Indirect immunofluorescent detection of antibodies against thermophilic actinomycetes in patients with hypersensitivity pneumonitis.
    Kurup VP; Barboriak JJ; Fink JN
    J Lab Clin Med; 1977 Mar; 89(3):533-9. PubMed ID: 402432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages.
    Kozel TR; Gotschlich EC
    J Immunol; 1982 Oct; 129(4):1675-80. PubMed ID: 7050244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.